Australia's most trusted
source of pharma news
Thursday, 17 April 2025
Posted 7 April 2025 AM
The first potential rival to Bayer’s blockbuster eye drug Eylea has officially landed in Australia with the TGA approving Celltrion Healthcare’s biosimilar Eydenzelt.
In the year to February, Eylea earned Bayer a massive $464.8 million in pre-rebate PBS benefits, a 6.6 per cent year-on-year increase.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.